the aid library

Orientação dinâmica da OMS: Medicamentos para prevenção da COVID-19 : 2 DE MARÇO DE 2021

Organização Mundial da Saúde (OMS) OPAS (2021) C_WHO

Resumo: o que é esta orientação dinâmica? Pergunta clínica: qual é o papel dos medicamentos na prevenção da COVID-19? Público-alvo: o público-alvo são os médicos e os tomadores de decisão na área da saúde. Prática atual: o uso atual de medicamentos para prevenção da COVID-19 é ... variável, refletindo uma incerteza em grande escala. Numerosos estudos clínicos randomizados de muitos medicamentos estão em andamento para orientar melhor a prática. Esta primeira versão de Medicamentos para prevenção da COVID-19: Orientação dinâmica da OMS contém novas informações e uma recomendação sobre a hidroxicloroquina. (1) Segue-se a publicação de seis estudos sintetizados em uma meta-análise dinâmica de rede (NMA). more

Le fonctionnement de la prise en charge des patients séropositifs au Bénin, le cas de l’Atacora

Perrine Bonvalet (2006) C2

Le fonctionnement de la prise en charge des patients séropositifs au Bénin, le cas de l’Atacora

Prioritised research agenda for prevention and control of chronic respiratory diseases

Bousquet, J.; Kiley, J.; Bateman, E.D. European Respiratory Journal (ERJ) (2010) C_WHO

The article outlines the prioritized research agenda for the prevention and control of chronic respiratory diseases (CRDs) as part of the World Health Organization's (WHO) action plan on noncommunicable diseases (NCDs) from 2008 to 2013. It highlights the significant global impact of CRDs, including ... asthma, chronic obstructive pulmonary disease (COPD), and other related conditions, particularly in low- and middle-income countries (LMICs). The document stresses the need for effective prevention strategies and better surveillance, as well as enhanced healthcare infrastructure and resources in LMICs. It calls for research into CRD risk factors, effective interventions, and integrated care approaches that align with broader NCD prevention programs. The article emphasizes the importance of public health initiatives and cross-sector collaborations to reduce the disease burden and improve patient outcomes. more

Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries

Reusken C. B. E. M., E. K. Broberg, B. Haagmans et al. Eurosurveillance (2020) C2

Timely detection of novel coronavirus (2019-nCoV) infection cases is crucial to interrupt the spread of this virus. We assessed the required expertise and capacity for molecular detection of 2019-nCoV in specialised laboratories in 30 European Union/European Economic Area (EU/EEA) countries. Thirty- ... eight laboratories in 24 EU/EEA countries had diagnostic tests available by 29 January 2020. A coverage of all EU/EEA countries was expected by mid-February. Availability of primers/probes, positive controls and personnel were main implementation barriers. more